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ABSTRACT Coronaviruses (CoVs) have emerged from animal reservoirs to cause se-
vere and lethal disease in humans, but there are currently no FDA-approved antivi-
rals to treat the infections. One class of antiviral compounds, nucleoside analogues,
mimics naturally occurring nucleosides to inhibit viral replication. While these com-
pounds have been successful therapeutics for several viral infections, mutagenic nu-
cleoside analogues, such as ribavirin and 5-fluorouracil, have been ineffective at in-
hibiting CoVs. This has been attributed to the proofreading activity of the viral 3=-5=
exoribonuclease (ExoN). -D-N4-Hydroxycytidine (NHC) (EIDD-1931; Emory Institute
for Drug Development) has recently been reported to inhibit multiple viruses. Here,
we demonstrate that NHC inhibits both murine hepatitis virus (MHV) (50% effective
concentration [EC50]  0.17 M) and Middle East respiratory syndrome CoV (MERS-
CoV) (EC50  0.56 M) with minimal cytotoxicity. NHC inhibited MHV lacking ExoN
proofreading activity similarly to wild-type (WT) MHV, suggesting an ability to evade
or overcome ExoN activity. NHC inhibited MHV only when added early during infec-
tion, decreased viral specific infectivity, and increased the number and proportion of
G:A and C:U transition mutations present after a single infection. Low-level NHC re-
sistance was difficult to achieve and was associated with multiple transition muta-
tions across the genome in both MHV and MERS-CoV. These results point to a virus-
mutagenic mechanism of NHC inhibition in CoVs and indicate a high genetic barrier
to NHC resistance. Together, the data support further development of NHC for treat-
ment of CoVs and suggest a novel mechanism of NHC interaction with the CoV rep-
lication complex that may shed light on critical aspects of replication.
IMPORTANCE The emergence of coronaviruses (CoVs) into human populations from
animal reservoirs has demonstrated their epidemic capability, pandemic potential,
and ability to cause severe disease. However, no antivirals have been approved to
treat these infections. Here, we demonstrate the potent antiviral activity of a broad-
spectrum ribonucleoside analogue, -D-N4-hydroxycytidine (NHC), against two diver-
gent CoVs. Viral proofreading activity does not markedly impact sensitivity to NHC
inhibition, suggesting a novel interaction between a nucleoside analogue inhibitor
and the CoV replicase. Further, passage in the presence of NHC generates only low-
level resistance, likely due to the accumulation of multiple potentially deleterious
transition mutations. Together, these data support a mutagenic mechanism of inhi-
bition by NHC and further support the development of NHC for treatment of CoV in-
fections.
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The emergence of severe acute respiratory syndrome (SARS) in 2002 and Middle Eastrespiratory syndrome (MERS) in 2012 has underscored the ability of coronaviruses
(CoVs) to cause lethal disease in humans (1, 2). MERS-CoV continues to infect humans 
in the Middle East, and four additional human CoVs (HCoVs), HCoV-229E, HCoV-NL63, 
HCoV-OC43, and HCoV-HKU1, continue to circulate globally and cause respiratory 
disease (3–6). The continued circulation in bat populations of SARS- and MERS- like 
CoVs that can replicate efficiently in primary human airway cells further demonstrates 
the potential for CoVs to emerge and cause severe disease in the future (7–10). While 
SARS-CoV and MERS-CoV outbreaks have been controlled, largely through public 
health measures (11–13), the potential for future outbreaks highlights the need for safe 
and effective therapeutics to combat CoV infections. There are currently no approved 
therapeutics or vaccines for any human CoV infection. Previous efforts to treat CoV 
infections with existing antivirals did not conclusively benefit clinical outcomes; thus, 
the current standard of care remains mostly supportive (14–16).
Several targets for direct-acting antivirals are being investigated to treat CoV 
infections (17–19). Because the viral replication machinery performs an essential role in 
genome replication, therapeutics approved to treat multiple different viral infections 
are aimed at this target (20). Many approved antivirals are classified as nucleoside 
analogues, compounds that mimic natural nucleosides to inhibit viral replication (21). 
Inhibition by nucleoside analogues can be accomplished through a variety of mecha-
nisms. Common mechanisms of action include incorporation of the analogue by the 
viral polymerase to induce premature termination of strand synthesis and loss of 
essential genetic information through mutagenesis (22–25). A previous study reported 
that the nucleoside analogues ribavirin (RBV) and 5-fluorouracil (5-FU) did not potently 
inhibit CoVs, and this finding was attributed to the proofreading capabilities of the viral 
3=-5= exoribonuclease (ExoN) (26). Recent reports have demonstrated the inhibition of 
wild-type (WT) CoVs by nucleoside analogues such as galidesivir (BCX4430) and rem-
desivir (GS-5734) (27–29). While these compounds have shown efficacy against CoVs, 
administration of multiple compounds simultaneously may be required to effectively 
treat CoV infections and control the emergence of drug resistance, as has been 
demonstrated for other viral infections (30).
-D-N4-Hydroxycytidine (NHC) (EIDD-1931; Emory Institute for Drug Development), a 
cytidine analogue, has recently been shown to inhibit multiple viruses, including 
chikungunya virus, Venezuelan equine encephalitis virus (VEEV), respiratory syncytial 
virus (RSV), hepatitis C virus, norovirus, influenza A (IAV) and B viruses, and Ebola virus 
(31–36). Previous reports have demonstrated increased introduction of transition mu-
tations in viral genomes after treatment, as well as a high genetic barrier to resistance 
(31, 36). Antiviral activity of NHC has also been reported against the human -CoV 
HCoV-NL63, as well as the -CoV SARS-CoV (43, 44). Neither the NHC mechanism of 
action nor NHC resistance has been described for any CoV to date.
In this study, we investigated NHC inhibition and resistance in two divergent 
-CoVs, murine hepatitis virus (MHV) and MERS-CoV. We show that NHC potently 
inhibits WT MHV and MERS-CoV with minimal cytotoxicity. We also demonstrate that 
MHV ExoN proofreading activity has a limited but measurable effect on sensitivity to 
NHC. We observed an NHC inhibition profile consistent with a mutagenic mechanism 
of action featuring an accumulation of transition mutations, indicative of a high genetic 
barrier to resistance.
RESULTS
NHC inhibits MHV and MERS-CoV replication with minimal cytotoxicity. NHC 
(Fig. 1) has potent broad-spectrum antiviral activity against many RNA viral families 
(31–36). We first determined if NHC also inhibits CoV replication, using a dose-response
FIG 1 Chemical structure of EIDD-1931, -D-N4-hydroxycytidine.
experiment with two divergent -CoVs: the model CoV MHV and the epidemically 
circulating zoonotic CoV MERS-CoV. NHC treatment resulted in a dose-dependent 
reduction in viral titers for MHV (Fig. 2A) and MERS-CoV (Fig. 2B). This inhibition resulted 
in 50% effective concentrations (EC50s) of 0.17 M for MHV (Fig. 2C) and 0.56 M for 
MERS-CoV (Fig. 2D). We detected negligible changes in DBT-9 cell viability out to
200 M (Fig. 2E) and 50% cytotoxic concentration (CC50) values above 10 M in Vero
cells (Fig. 2F). The antiviral activity was not due to cytotoxicity, as the selectivity indexes 
were 1,000 for MHV and 20 for MERS-CoV. Together, these results confirm potent 
inhibition of -CoVs by NHC.
The NHC inhibition profile in CoVs is consistent with mutagenesis. To better 
understand the mechanism through which NHC inhibits CoV replication, we performed 
a time of drug addition assay to determine at what point in the viral replication cycle 
NHC acts (40). We added 16 M (100 times the EC50) NHC at the indicated times pre-
or postinfection (p.i.) of cells with WT MHV at a multiplicity of infection (MOI) of 1 
PFU/cell and quantified viral replication after a single infectious cycle. Compared to the 
vehicle (dimethyl sulfoxide [DMSO]) control, NHC significantly inhibited MHV replica-
tion when added at or before 6 h postinfection (Fig. 3A), suggesting that NHC acts at 
early stages of the viral replication cycle. We next determined the effect of NHC on MHV 
RNA levels and compared it to the effect on the infectious-virus titer. RNA levels were 
reduced by approximately 10-fold at the highest tested concentration of NHC in both 
MHV-infected cell monolayers (Fig. 3B) and supernatants (Fig. 3C). In contrast, the viral 
titer was reduced up to 5,000-fold at this concentration. We therefore calculated the 
ratio of infectious virus per viral RNA genome copy number normalized to the un-
treated control (specific infectivity) after NHC treatment and found that the specific 
infectivity of WT MHV was reduced in a dose-dependent manner after treatment with 
increasing concentrations of NHC (Fig. 3D). Together, these data are consistent with a 
mutagenic mechanism of NHC anti-CoV activity.
NHC treatment increases transition mutations present across the MHV ge-
nome. To directly test the effect of NHC treatment on the mutational burden, we 
treated WT MHV with increasing concentrations of NHC and performed full-genome 
next-generation sequencing (NGS) on viral populations released after a single round of 
infection. Our data demonstrated a dose-dependent increase in mutations present at 
low frequencies (5% of the viral population) across the genome after treatment with 
increasing concentrations of NHC (Fig. 4A to C). Further analysis of the types of 
mutations introduced by NHC revealed an increase in the total number of transition 
mutations with increasing NHC concentrations (Fig. 4D to F). The relative proportions 
of G:A and C:U transitions among all observed mutations were increased by 13 to 15%
in the presence of 2 M NHC and 36 to 40% in the presence of 4 M NHC compared
FIG 2 NHC inhibits MHV and MERS-CoV with minimal cytotoxicity. (A and B) Changes in MHV (A) and MERS-CoV
(B) titers relative to vehicle control after treatment with increasing concentrations of NHC. The data represent the
results of 6 independent experiments, each with 3 replicates. The error bars represent standard errors of the mean
(SEM). (C) Changes in titer data from panel A, represented as percentages of that of vehicle control. WT MHV,
EC50  0.17 M. (D) Changes in titer data from panel B, represented as percentages of that of vehicle control. WT
MERS-CoV, EC50  0.56 M. (E) DBT-9 cell viability as a percentage of that of DMSO control across NHC
concentrations. No cytotoxicity was detected up to 200 M. The data represent the results of 2 independent
experiments, each with 2 replicates (MHV). The error bars represent SEM. (F) Vero cell viability as a percentage of
that of DMSO control across NHC concentrations. Less than 50% cytotoxicity was detected up to 10 M. The data
represent the results of 2 independent experiments, each with 3 replicates. The error bars represent SEM.
to the vehicle control (Fig. 4G and H). Conversely, the relative proportions of A:G and 
U:C transitions decreased with increasing NHC concentrations compared to the vehicle 
control (Fig. 4G and H). Together, these results demonstrate that NHC treatment during 
a single round of WT MHV infection causes predominantly G:A and C:U transition 
mutations that are detectable at low frequencies across the genome. These data further 
support a mutagenic mechanism of action for NHC inhibition of WT MHV.
NHC inhibition is modestly enhanced in the absence of ExoN proofreading. 
Mutagenic nucleoside analogues, such as RBV and 5-FU, have been ineffective at 
potently inhibiting WT CoVs due to the ExoN proofreading activity (26). A proofreading-
deficient [ExoN()] MHV mutant displays increased sensitivity to previously tested 
nucleoside analogues, indicating that proofreading dampens inhibition by these com-
pounds (26, 37, 38). Therefore, we tested the sensitivity of ExoN() MHV to NHC 
inhibition. Our results indicate that NHC decreases the titers of both WT and ExoN() 
MHV in a dose-dependent manner but that ExoN() MHV demonstrates a statistically
significant increase in sensitivity to NHC inhibition compared to WT MHV (Fig. 5A).
FIG 3 The NHC inhibition profile of MHV is consistent with mutagenesis. (A) Treatment with 16 M NHC (100
times the EC50) significantly inhibits MHV replication during a single infection when added before 6 h p.i. (B) Both
MHV titer and monolayer RNA copies decrease after treatment with increasing concentrations of NHC. (C) NHC
treatment results in a decrease in supernatant MHV RNA. (D) Data from panel C represented as the ratio of
infectious WT MHV to genomic MHV RNA present in the supernatant, or specific infectivity, normalized to that of
vehicle control. NHC treatment resulted in a decrease in the specific infectivity of MHV. All the data represent the
results of 2 independent experiments, each with 3 replicates. The error bars represent SEM. Statistical significance
compared to DMSO control was determined by one-way analysis of variance (ANOVA) with Dunnett’s post hoc test
for multiple comparisons. *, P  0.05; **; P  0.01; ***, P  0.001; ****, P  0.0001.
However, this difference is reflected in only a modest decrease in the EC90 (approxi-
mately 2-fold) for ExoN() MHV (0.72 M) compared to WT MHV (1.59 M) (Fig. 5B). The 
minimal change in sensitivity to NHC observed for ExoN() MHV indicates that NHC 
potency is only marginally affected by ExoN proofreading activity.
Passage in the presence of NHC yields low-level resistance associated with 
multiple transition mutations. To better understand the development and impact of 
NHC resistance in CoVs, we passaged two lineages of WT MHV 30 times in the presence 
of increasing concentrations of NHC and tested the sensitivity of passage 30 (p30) MHV 
populations to NHC inhibition. We found that the lineage 1 (MHV p30.1) viral popula-
tion showed no change in sensitivity to NHC compared to WT MHV (Fig. 6A). However, 
lineage 2 (MHV p30.2) showed a decrease in sensitivity to NHC inhibition in a titer 
reduction assay, especially at higher concentrations of compound. We observed a 
modest (approximately 2-fold) increase in EC90 values for MHV NHC passage viruses 
(WT MHV, EC90  1.53 M; MHV p30.1, EC90  2.61 M; MHV p30.2, EC90  2.41 M)
(Fig. 6B). This suggests that MHV passage resulted in minimal resistance to NHC. We 
next sought to determine if passaging WT MHV in the presence of NHC altered the 
replication capacities of these viruses. We found that both lineages showed a delay in 
replication but ultimately reached peak titers similar to that of WT MHV (Fig. 6C). This 
delay in replication suggests that MHV p30 is less fit than WT MHV.
To identify mutations associated with these phenotypes after passage, we se-
quenced complete genomes of MHV p30.1 and MHV p30.2. Both lineages passaged in 
the presence NHC had accumulated over 100 consensus mutations distributed across 
the genomes (Fig. 6D and E; see Table S1 in the supplemental material). In comparison, 
a previous study reported that WT MHV accumulated only 23 total mutations after 250
passages in the absence of drug (38). Further analysis of the p30 MHV mutational
profile demonstrated that slightly more of the total mutations in both lineages were
synonymous changes that did not result in an amino acid change as opposed to
nonsynonymous changes, which did alter the amino acid sequence (Fig. 6F; see
FIG 4 NHC treatment drives an increase in low-frequency G:A and C:U transition mutations in WT MHV during a single infection. (A to C) Distribution and
frequencies of variants across the genome detected by NGS after vehicle treatment (A), 2 M NHC treatment (B), or 4 M NHC treatment (C). The log10 depth
of coverage at each genomic position is depicted by the lines; the frequencies of individual mutations spread across the genome are represented by the dots.
(D to F) Numbers of mutations in WT MHV after infection in the presence of vehicle (D), 2 M NHC (E), or 4 M NHC (F) presented by type. Transition mutations
are shown in gray, and transversion mutations are shown in white. (G and H) Changes in relative proportions of each mutation type after treatment with 2 M
NHC (G) or 4 M NHC (H) compared to vehicle control. The relative proportions of G:A and C:U transitions increased with increasing concentrations of NHC
treatment and are indicated by green shading.
FIG 5 Sensitivity of ExoN() MHV to inhibition by NHC. (A) Changes in viral titers for WT MHV and ExoN() MHV 
relative to vehicle control after treatment with NHC. ExoN() MHV is more sensitive to NHC than WT MHV. The data 
represent the results of 3 independent experiments, each with 3 replicates. The error bars represent SEM. Statistical 
significance compared to WT MHV was determined by a Wilcoxon test. **, P  0.01. (B) Changes in viral titer data 
from panel A represented as a percentage of that in vehicle control. WT, EC90  1.59 M; ExoN(), EC90  0.72 M. 
ExoN() MHV is approximately 2-fold more sensitive to NHC than WT MHV.
FIG 6 Resistance and mutational profiles of MHV after 30 passages in the presence of NHC. (A) Changes in viral titers for WT MHV, MHV p30.1, and MHV p30.2
relative to vehicle controls after treatment with NHC. MHV NHC p30.2 was less sensitive to NHC than WT MHV, while MHV p30.1 showed no change in sensitivity.
The data represent the results of 2 independent experiments, each with 3 replicates. The error bars represent SEM. Statistical significance compared to WT MHV
was determined by ratio paired t test. *, P  0.05. (B) Changes in viral titer data from panel A represented as percentages of that of vehicle control. WT MHV,
EC90  1.53 M; MHV p30.1, EC90  2.61 M; MHV p30.2, EC90  2.41 M. (C) Replication kinetics of NHC passage viruses. MHV p30.1 and p30.2 were delayed
in replication compared to WT MHV but ultimately reached similar peak titers. The data represent the results of 2 independent experiments, each with 3
replicates. The error bars represent standard deviations (SD). (D) MHV p30.1 accumulated a total of 162 consensus mutations across the genome that were
detectable by Sanger sequencing. Of these mutations, 81 were synonymous, 64 were nonsynonymous, and 17 were noncoding. (E) MHV p30.2 accumulated
102 total mutations across the genome. Of these mutations, 54 were synonymous, 42 were nonsynonymous, and 7 were noncoding. (F) Each lineage
accumulated more synonymous changes than nonsynonymous or noncoding changes over passage. (G) Breakdown of transition and transversion mutations
present in each lineage after passage. MHV p30.1 and p30.2 mutations were predominantly transitions. (H) Breakdown of the types of transition mutations
present in each lineage across passage. G:A transitions were the most abundant for both MHV p30.1 and p30.2.
Table S1). Additionally, the vast majority of mutations in both lineages were transition 
mutations resulting in a purine-to-purine or pyrimidine-to-pyrimidine change (Fig. 6G). 
Both lineages contained only two transversion mutations resulting in a purine-to-
pyrimidine or pyrimidine-to-purine change. Though all possible transition mutation 
types were detected in both viral-lineage populations, the majority in both passage 
lineages were G:A transitions (Fig. 6H), which is consistent with the MHV NGS data (Fig. 
4). To determine if the mutational profile at p30 was consistent with an earlier passage, 
we analyzed the whole genomes of both lineages 1 and 2 at p19. Both lineages 
demonstrated fewer mutations at p19 than at p30, but the profiles of synonymous 
versus nonsynonymous changes and the transition mutations were similar (see Fig. S1 
and Table S2 in the supplemental material).
To determine whether the lack of robust resistance to NHC was broadly applicable 
across  -CoVs, we assessed the capacity of MERS-CoV to evolve resistance to NHC. As
FIG 7 Resistance and mutational profiles of MERS-CoV after 30 passages in the presence of NHC. (A) Changes in viral titers relative to vehicle controls after
treatment with NHC for WT MERS-CoV passaged 30 times in the absence of drug, MERS-CoV p30.1, and MERS-CoV p30.2 relative to vehicle controls after
treatment with NHC. Both MERS-CoV p30.1 and p30.2 were less sensitive to NHC than WT MERS-CoV. The data represent the results of 2 independent
experiments, each with 3 replicates. The error bars represent SEM. (B) Changes in viral titer data from panel A represented as percentages of that of vehicle
control. WT MERS-CoV, EC90  1.31 M; MERS-CoV p30.1, EC90  3.04 M; MERS-CoV p30.2, EC90  2.12 M. (C) Replication kinetics of NHC passage viruses.
WT MERS-CoV, MERS-CoV p30.1, and MERS-CoV p30.2 replicated with similar kinetics and reached similar peak titers. The data represent the results of 2
independent experiments, each with 3 replicates. The error bars represent SEM. (D) MERS-CoV p30.1 accumulated 27 total mutations across the genome. Of
these mutations, 14 were synonymous and 13 were nonsynonymous. (E) MERS-CoV p30.2 accumulated 41 total mutations. Of these mutations, 17 were
synonymous and 24 were nonsynonymous. (F) Both MERS-CoV p30.1 and p30.2 accumulated similar numbers of nonsynonymous and synonymous changes
during passage. (G) MERS-CoV p30.1 and p30.2 acquired predominantly transitions. (H) Types of transition mutations present in each lineage across passage.
MERS-CoV p30.1 acquired more G:A transitions, whereas MERS-CoV p30.2 acquired similar numbers of each transition type.
with MHV, we passaged two lineages of MERS-CoV 30 times in the presence of 
increasing concentrations of NHC and tested the sensitivities of the lineages to inhi-
bition by NHC. Compared to WT MERS-CoV passaged in the absence of drug, both 
MERS-CoV NHC p30.1 and p30.2 exhibited decreased sensitivity to NHC inhibition (Fig. 
7A). This correlated with modestly increased EC90 values for the passage lineages (WT 
MERS-CoV, EC90  1.31 M; MERS-CoV p30.1, EC90  3.04 M; MERS-CoV p30.2, EC90  
2.12 M) (Fig. 7B), corresponding to approximately 2-fold resistance. Similar to MHV, we 
observed no substantial shift in the dose-response curve for MERS-CoV, indicating 
minimal acquired resistance. NHC p30 viruses replicated similarly to WT p30 MERS-CoV 
(Fig. 7C). We sequenced both lineages of the MERS-CoV p30 population and detected 
27 consensus mutations in MERS-CoV NHC p30.1 (Fig. 7D; see Table S3 in the supple-
mental material) and 41 consensus mutations in MERS-CoV NHC p30.2 (Fig. 7E; see 
Table S3) that were randomly distributed across the genome. Both MERS-CoV NHC 
p30.1 and MERS-CoV NHC p30.2 accumulated nonsynonymous and synonymous mu-
tations in roughly equal proportions (Fig. 7F). As in MHV, the mutations detected in 
MERS-CoV p30 lineages were predominantly transition mutations (Fig. 7G). Further 
analysis of these mutations revealed that the predominant type of transition was 
lineage dependent. The majority of transition mutations in MERS-CoV NHC p30.1 were 
G:A transitions, as was observed in both p30 MHV lineages, whereas MERS-CoV NHC 
p30.2 contained similar numbers of each type (Fig. 7H). These results indicate that 
MERS-CoV can achieve low-level resistance to NHC and that development of resistance 
is associated with the accumulation of multiple transition mutations. Together, our data 
suggest NHC acts as a mutagen and that it poses a high genetic barrier to resistance 
for -CoVs.
DISCUSSION
In this study, we demonstrate that NHC potently inhibits the divergent -CoVs MHV 
and MERS-CoV. Our data are consistent with a virus-mutagenic mechanism of action, as 
evidenced by a decrease in specific infectivity and an increase in G:A and C:U transition 
mutations present at low frequencies across the genome after treatment with NHC. We 
also demonstrate that robust resistance to NHC is difficult to achieve in both MHV and 
MERS-CoV. Both WT MHV and ExoN() MHV are sensitive to NHC inhibition, suggesting 
that NHC is able to overcome ExoN-mediated proofreading to inhibit WT CoVs and that 
it interacts with CoVs differently than other previously tested nucleoside analogues.
Utility of the broad-spectrum antiviral NHC as a pan-CoV therapeutic. Early 
work with NHC focused on the mutagenic effects of the compound in multiple bacterial 
systems (39, 41, 42). More recently, the antiviral properties of the compound have been 
reported for multiple RNA viruses, including chikungunya virus, Venezuelan equine 
encephalitis virus, respiratory syncytial virus, hepatitis C virus, norovirus, influenza A 
and B viruses, and Ebola virus (31–36). NHC has also been shown to potently inhibit 
SARS-CoV and HCoV-NL63 (43, 44), suggesting potential utility in treating CoV infec-
tions (17). Based on previous studies, NHC appears to primarily inhibit viral replication 
by mutagenesis (31, 34). Serial passaging in the presence of NHC led to low-level 
resistance for VEEV, but no detectable resistance for RSV, IAV, or bovine viral diarrhea 
virus, indicating a high barrier to resistance (31, 34, 36). Consistent with the previous 
studies, we demonstrated that NHC is mutagenic in CoVs and that serial passaging 
yields low-level, approximately 2-fold resistance. Low-level resistance has also been 
observed for remdesivir, another nucleoside analogue that potently inhibits CoVs. 
Approximately 6-fold resistance to remdesivir is conferred by two mutations in the CoV 
RNA-dependent RNA polymerase (RdRp) (37). This study further expands the known 
antiviral spectrum of NHC to include MHV and MERS-CoV, two genetically divergent 
-CoVs, and supports NHC development as a broad-spectrum CoV antiviral.
NHC inhibition may circumvent ExoN-mediated proofreading. NHC is the first 
mutagenic nucleoside analogue demonstrated to potently inhibit proofreading-intact 
CoVs. Previous studies have demonstrated that viruses lacking ExoN proofreading 
activity [ExoN() viruses] are more sensitive to inhibition by nucleoside analogues, 
especially RBV and 5-FU (26, 37, 38, 45). This increased sensitivity has been attributed 
to the inability of ExoN() viruses to efficiently remove incorrect nucleosides (46). 
However, we observed a minimal change in NHC sensitivity between WT MHV and 
ExoN() MHV, especially by EC90. This suggests that NHC interacts with the CoV 
replicase differently than other previously tested nucleoside analogues. One explana-
tion is that NHC may evade removal by the proofreading ExoN. Studies investigating 
nucleosides that inhibit DNA viruses have suggested an inability of the viral exonu-
clease to efficiently excise some nucleoside analogues (47, 48). Further, a previous study 
suggested that the T4 DNA exonuclease activity was incapable of removing NHC (49). 
While the SARS-CoV ExoN efficiently removes 3=-terminal mismatches regardless of 
type (46, 50), the effect of NHC on this activity has not been investigated. Interestingly, 
mismatches readily observed during single-nucleotide elongation by the SARS-CoV 
polymerase in the absence of drugs correspond to mismatches that would lead to the 
G:A and C:U transitions observed after NHC treatment (46). This suggests that the CoV
polymerase could be naturally more prone to make these types of errors, which are then 
magnified by NHC. This could lead to a scenario where ExoN cannot prevent dipping 
below the error threshold, ultimately resulting in lethal mutagenesis and similar 
inhibition of both WT MHV and ExoN() MHV (51).
Several nucleosides, including the mutagenic RBV, have multiple demonstrated 
mechanisms other than direct incorporation into the genome (52, 53). Thus, another 
explanation for the unique potency of NHC in the presence of an active proofreading 
ExoN is that it may inhibit viral replication by additional mechanisms beyond mutagen-
esis. Indeed, previous reports have suggested that NHC may also interfere with the RNA 
secondary structure or virion release to cause inhibition (31, 36). Further, exogenous C or 
U in the presence of NHC could rescue viral replication in HCV, chikungunya virus, RSV, 
and influenza A virus (32, 34, 36), indicating that NHC competes with exogenous 
nucleosides at some stage prior to viral inhibition. These results raise the possibility that 
NHC could inhibit a process that results in similar inhibition of these viruses by a 
mechanism unrelated to ExoN. Thus, future studies will be important to investigate the 
role of proofreading in NHC inhibition of CoVs to shed light on the intricacies of NHC 
inhibition of the CoV replication complex.
NHC mutagenesis may hinder emergence of robust resistance to NHC. The de-
crease in specific infectivity, along with the accumulation of transitions across the CoV 
genome, supports a mutagenic mechanism of action for NHC in CoVs. NHC resistance in 
CoVs was modest and difficult to achieve, as we obtained approximately 2-fold 
resistance after 30 passages. Resistance was associated with multiple mutations. Inter-
estingly, MERS-CoV accumulated fewer mutations over 30 passages than MHV. While 
differences in viral mutation rates could be the driver of this difference, previous studies 
have suggested that MHV does not have a higher mutation rate than MERS-CoV (54–56). 
The differences in mutation accumulation between MHV and MERS-CoV may be a 
product of different passage conditions. While MHV was passaged with a consis-tent 
transfer volume, MERS-CoV passage volumes were adjusted over time to sustain viral 
replication under escalating selection for drug resistance. The constant-volume 
passaging conditions may have more severely bottlenecked MHV populations and fixed 
more mutations in the genome than the variable-volume passaging conditions applied 
to MERS-CoV (57). Alternatively, this difference could also reflect a difference in 
mutational robustness of the MHV and MERS-CoV genomes, though this proposition 
needs to be investigated further (58, 59). While a portion of the mutations that 
accumulated during passage likely contribute to NHC resistance, mutations in proteins 
dispensable for viral replication in cell culture, such as ns2 and nsp2, may be merely 
tolerated because of their limited effect on viral fitness in the context of our passage 
conditions (60–62). Few common mutations arose in both MHV and MERS-CoV passage 
series (see Tables S1 to S3), suggesting that multiple pathways to low-level NHC 
resistance exist in CoVs. Interestingly, for both MHV and MERS-CoV, the p30 lineage that 
demonstrated a greater change in sensitivity to NHC was the lineage that had fewer 
overall mutations (Fig. 6 and 7). Both MHV passage lineages replicated less well than WT 
MHV, suggesting that the accumulation of mutations during passage may nega-tively 
impact viral fitness and the ability of MHV to evolve robust resistance to NHC. Further, 
the MHV lineage that did not result in changed sensitivity to NHC by p30 (MHV p30.1) 
had fewer mutations present at consensus by p19 than the other lineage (see Fig. S1). 
Thus, it is possible that the accumulation of deleterious mutations counteracts the 
potential benefits of resistance mutations (63). If this is the case, mutations promoting 
NHC resistance would need to arise early during passage to help mitigate the 
accumulation of excess deleterious mutations. Alternatively, the inability to evade 
inhibition by NHC may lead to the accumulation of a greater number of NHC-associated 
transitions and ultimately a higher mutational burden that may impact viral fitness (64, 
65). Together, our results support the hypothesis that establishment of resistance to 
NHC in CoVs requires a delicate balance of resistance-promoting mutations, viral fitness, 
and accumulation of deleterious mutations. Thus, defining the roles of individ-
ual NHC resistance-associated mutations will be an important goal for future studies.
Overall, our results support further development of NHC as a broad-spectrum antiviral
for treatment of CoV infections and contribute new insights into important aspects of
CoV replication.
MATERIALS AND METHODS
Cell culture. Murine astrocytoma delayed brain tumor (DBT) (66) and Vero (ATCC CCL-81) cells were 
maintained at 37°C in Dulbecco’s modified Eagle medium (DMEM) (Gibco) supplemented with 10% fetal 
bovine serum (FBS) (Invitrogen), 1% penicillin and streptomycin (Gibco), and 0.1% amphotericin B 
(Corning).
Viruses. All work with MHV was performed using the recombinant WT strain MHV-A59 (GenBank 
accession number AY910861 [67]). MERS-CoV stocks were generated from cDNA clones (GenBank 
accession number JX869059 [68]).
Compounds and cell viability studies. NHC was synthesized at the Emory Institute for Drug 
Development and prepared as a 20 mM stock solution in DMSO. Cell viability was assessed using 
CellTiter-Glo (Promega) in 96-well plates according to the manufacturer’s instructions. DBT and Vero cells 
were incubated with the indicated concentrations of compound at 37°C for 24 h (DBT) or 48 h (Vero). Cell 
viability was determined using a Veritas Microplate luminometer (Promega) or GloMax (Promega), with 
values normalized to those of vehicle-treated cells.
Nucleoside analogue sensitivity studies and generation of EC50 curves. Subconfluent monolay-
ers of DBT cells were infected with MHV at an MOI of 0.01 PFU per cell for 1 h at 37°C. The inoculum was 
removed and replaced with medium containing the indicated compound concentration. Cell superna-
tants were harvested 24 h postinfection. Titers were determined by plaque assay as described previously 
(69). Subconfluent monolayers of Vero cells were infected at an MOI of 0.01 PFU/cell of MERS-CoV. After 
virus adsorption for 30 min at 37°C, the inoculum was removed. The cells were washed with PBS and 
incubated with medium containing the indicated concentrations of NHC or DMSO (vehicle control). After 
48 h, the supernatant was collected and titers were determined by plaque assay as described previously 
(70). EC50 and EC90 values and curves were generated using the nonlinear regression curve fit in 
GraphPad (La Jolla, CA) Prism software.
Time of drug addition assay. Subconfluent monolayers of DBT cells were treated with medium 
containing DMSO or 16 M NHC (100 times the EC50) at the indicated times pre- or postinfection. The 
cells were infected with WT MHV at an MOI of 1 PFU/cell for 1 h at 37°C. The virus inoculum was removed 
and replaced with fresh medium. Culture supernatant was harvested 12 h postinfection, and the viral titer 
was determined by plaque assay.
Quantification of viral genomic RNA. Subconfluent DBT cells were infected with WT MHV at an MOI 
of 0.01 PFU/cell. The inoculum was removed after 1 h of incubation at 37°C, and medium containing the 
indicated concentration of NHC was added. Total RNA from cells and supernatant RNA were harvested 
using TRIzol reagent (Invitrogen) after 20 h. Both total RNA and supernatant RNA were extracted by 
phase separation. Total RNA was purified by ethanol precipitation, and supernatant RNA was purified 
using a PureLink RNA minikit (Invitrogen) according to the manufacturer’s protocol. Total RNA was 
reverse transcribed using SuperScript III (Invitrogen) to generate cDNA, which was quantified by 
quantitative PCR (qPCR) as previously described (26). Data are presented as 2ΔΔCT, where ΔΔCT denotes 
the change in the threshold cycle for the viral target (nsp10) normalized to the control (glyceraldehyde-
3-phosphate dehydrogenase [GAPDH]) before and after drug treatment. The supernatant RNA was 
quantified using one-step quantitative reverse transcriptase PCR (qRT-PCR) as previously described (45). 
The data are presented as the fold change in genome RNA copies normalized to vehicle control.
Determination of specific infectivity. Subconfluent DBT cells were infected with WT MHV at an MOI 
of 0.01 PFU/cell. The inoculum was removed after 1 h of incubation at 37°C, and medium containing the 
indicated concentration of NHC was added. Supernatant RNA was harvested using the TRIzol reagent 
(Invitrogen) after 20 h, followed by extraction and quantification as described above. The viral titer was 
determined by plaque assay. The specific infectivity was calculated as the number of PFU divided by the 
supernatant genome RNA copy number. This ratio was then normalized to that of the vehicle control.
NGS studies. Subconfluent DBT cells were infected with WT MHV at an MOI of 0.01 PFU/cell and 
treated with the indicated concentrations of NHC. The supernatant was collected 24 h postinfection. 
Purified viral RNA was submitted to Genewiz (South Plainfield, NJ) for library preparation and sequencing. 
Briefly, after quality controls, viral RNAs were randomly fragmented using heat. Libraries were prepared 
and sequenced on the Illumina HiSeq platform.
Genewiz performed base calling and read demultiplexing. Trimmomatic was used to trim adapter 
contaminants and reads shorter than 36 bp and to filter low-quality bases (Q score  30) (71). The 
paired-end fastq reads were then aligned with the MHV genome using Bowtie2 to generate a SAM file 
(72). SAMtools was used to process the resultant alignment file and to calculate the coverage depth at 
each nucleotide, generating a sorted and indexed BAM file. LoFreq was used to call substitution variants, 
including low-frequency variants, and to generate a variant file (73). The Bash shell and Excel were used 
to further process and analyze the resultant vcf file. A frequency of 0.001 was used as a cutoff for variants, 
consistent with previous reports (74). Absolute numbers of mutations are reported for each NHC 
treatment. The percentage of the total mutations for each specific mutation type was calculated using 
these numbers. The difference in percentage for each class of mutation after treatment compared with 
vehicle control is referred to as the relative proportion of these mutations.
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